China reported more than 1.2 million cases of adverse drug reactions (ADRs) in 2012, with anti-infection drugs accounting for 40 percent of the total, according to a report from the State Food and Drug Administration (SFDA) Thursday. Highlighting cephalosporin as causing the greatest number of ADR cases among anti-infection drugs, senior SFDA official Yan Min called for manufacturing companies to research the drug\'s ADR sources more thoroughly. Yan added that the use of anti-infection drugs has been effectively regulated, as the proportion of ADR resulting from these drugs has been continuously dropping. The ADR monitoring report noted that of the 1.2 million ADR cases, 81.6 percent involved chemical-based medicine, while traditional Chinese medicine (TCM) contributed 17.1 percent. Biological products accounted for the rest. New or severe adverse reactions accounted for 20 percent of the total, the report said. As injections took up the lion\'s share of the total cases with 56.7 percent, Yan urged health institutions to strengthen supervision over their use. Her urge echoed a recent call from the Ministry of Health to implement safer practices after local authorities in northeast China\'s Liaoning Province confirmed last month that 99 people had contracted hepatitis C at a private clinic from contaminated injections.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor